Labcorp announces additional information in connection with its spin-off of Fortrea

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5:00

Labcorp announces information in connection with its spin-off of Fortrea

BURLINGTON, N.C. , June 9, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"):     The record date will be 5 p.m.

Labcorp announces launch of Fortrea's Notes Offering in connection with anticipated spinoff

BURLINGTON, N.C. , June 8, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"), has launched an offering of senior secured notes due 2030 (the "Notes"), subject to market

Celebrating three years of building on RDL’s legacy

We are pleased to commemorate the three-year anniversary of Labcorp’s acquisition of RDL Reference Laboratory. Labcorp is fully committed to continuing RDL’s legacy of providing autoimmune testing services to aid with the diagnosis, treatment and management of complex autoimmune syndromes.

Labcorp Appoints Dr. Paul Rothman to Board of Directors

Health system executive brings three decades of medical enterprise experience to Labcorp BURLINGTON, N.C. , June 7, 2023 /PRNewswire/ --  Labcorp (NYSE: LH), a leading global life sciences company, today announced the appointment of Dr. Paul Rothman to its Board of Directors as an independent

7 ways to improve men’s health this June

In June, we celebrate Men’s Health Awareness, so it’s a great time to think about some important steps men can take to put their health first. Compared with women, men are at increased risk for a number of conditions, including heart disease, cancer, respiratory disease and more.

Comparison of immune microenvironment between primary and metastatic breast tumors

Rachel Smith, PhD

Dr. Rachel Smith is a research and development scientist for Labcorp Biopharmaceutical CMC Services. Her background is in mass spectrometry, and in addition to developing methods for LC-MS analysis of biotherapeutics, she leads the forced degradation and formulation development teams. Her particular focus has been on the development of workflows for intact and middle-up LC-MS characterization of mAbs and derivative fusion proteins, but she is experienced in all of the LC-MS biopharmaceutical characterization methods offered by Labcorp Biopharmaceutical CMC Services.